**Dapagliflozin-lowered blood glucose reduces respiratory P. aeruginosa infection in diabetic mice**

Annika Åstrand1, Cecilia Wingren1, Audra Benjamin2, John S. Tregoning3,James P. Garnett2,Helen Groves3, Simren Gill3, Maria Orogo-Wenn2, Anders J. Lundqvist1, Dafydd Walters2, David M. Smith4, John D. Taylor1, Emma H. Baker2 & Deborah L. Baines2

1Respiratory, Inflammation and Autoimmunity Innovative Medicines Research Unit, and 4Cardiovascular & Metabolic Diseases Innovative Medicines Research Unit, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden. 2 Institute for Infection and Immunity, St George’s, University of London, London SW17 0RE, UK. 3 Mucosal Infection & Immunity Group, Section of Virology, Imperial College London, St Mary’s Campus, London, W2 1PG, UK

**Corresponding Author**

Deborah Baines

Institute for Infection and Immunity,

St George’s, University of London,

London SW17 0RE, UK

[d.baines@sgul.ac.uk](mailto:d.baines@sgul.ac.uk)

**Key words:** airway epithelium, respiratory infection, bacterial infection,glucose, dapagliflozin, LPS, *P. aeruginosa*

**Running title: Dapagliflozin reduces *P. aeruginosa* infection**

**ABSTRACT**

**Background and Purpose**

Hyperglycaemia increases glucose concentrations in airway surface liquid (ASL) and increases the risk of pulmonary *Pseudomonas aeruginosa* infection. We determined whether reduction of blood and airway glucose concentrations by the anti-diabetic drug dapagliflozin could reduce *P. aeruginosa* growth/survival in the lungs of diabetic mice.

**Experimental Approach**

The effect of dapagliflozin on blood and airway glucose concentration, the inflammatory response and infection were investigated in C57BL/6J (wild type, WT) or db/db (leptin receptor-deficient) mice, treated orally with dapagliflozin prior to intranasal dosing with lipopolysaccharide (LPS) or inoculation with *P. aeruginosa*. Pulmonary glucose transport and fluid absorption was investigated in Wistar rats using the perfused fluid-filled lung technique.

**Key Results**

Fasting blood, airway glucose and lactate concentrations were elevated in the db/db mouse lung. LPS challenge increased inflammatory cells in BALF from WT and db/db mice with and without dapagliflozin treatment. *P. aeruginosa* colony-forming units (CFU) were increased in db/db lungs. Pre-treatment with dapagliflozin reduced blood and bronchoalveolar lavage glucose concentrations and *P. aeruginosa* CFU in db/db mice towards those seen in WT. Dapagliflozin had no adverse effects on the inflammatory response in the mouse or pulmonary glucose transport or fluid absorption in the rat lung.

**Conclusion and Implications**

Pharmacological lowering of blood glucose with dapagliflozin effectively reduced *P. aeruginosa* infection in the lungs of diabetic mice and had no adverse pulmonary effects in the rat. Dapagliflozin has potential to reduce the use, or augment the effect, of antimicrobials in the prevention or treatment of pulmonary infection.

Abstract Word Count: 248 / 250

**Non standard abbreviations**

ASL airway surface liquid

BALF bronchoalveolar lavage fluid

CFU colony forming units

CF cystic fibrosis

COPD chronic obstructive pulmonary disease

db/db leptin receptor deficient

SGLT sodium coupled glucose transporter

WT wild type

**Introduction**

People with diabetes mellitus are at increased risk of, and have worse outcomes from, lower respiratory tract infections compared to those without diabetes mellitus. This is a particular problem in chronic lung disease, where diabetes is a common comorbidity. In people with chronic obstructive pulmonary disease (COPD), diabetes is associated with an increased likelihood and frequency of exacerbations ([Kinney *et al.*, 2014](#_ENREF_17)), and increased duration of hospital stay and mortality from exacerbations ([Gudmundsson *et al.*, 2006](#_ENREF_12); [Parappil *et al.*, 2010](#_ENREF_28)). In those with cystic fibrosis (CF), diabetes is an independent risk factor for pulmonary exacerbations ([Jarad *et al.*, 2008](#_ENREF_15); [Sawicki *et al.*, 2013](#_ENREF_34)) and for failure of intravenous or oral antibiotic treatment ([Briggs *et al.*, 2012](#_ENREF_4); [Parkins *et al.*, 2012](#_ENREF_30)). In both COPD and CF, poor glycaemic control is positively associated with exacerbation frequency ([Franzese *et al.*, 2008](#_ENREF_6); [Kupeli *et al.*, 2010](#_ENREF_18)).

An important mechanism whereby diabetes mellitus drives respiratory infection is through disruption of airway glucose homeostasis. In health, the glucose concentration of fluid lining human airways (airway surface liquid, ASL) is ~0.4mM, 12.5 times lower than blood glucose concentrations ([Baker *et al.*, 2007](#_ENREF_2)). Hyperglycaemia increases ASL glucose concentrations by three-fold in healthy lungs and ten-fold in chronic lung disease ([Baker *et al.*, 2007](#_ENREF_2)). Increased ASL glucose concentrations predispose to respiratory infection, both by promoting the growth of pathogenic organisms that use glucose as a carbon source, particularly *P. aeruginosa* and *S. aureus*, and by suppressing host immunity. In both cell culture and animal lung models, elevation of blood glucose concentrations increases ASL glucose concentrations, which in turn drives respiratory infection ([Garnett *et al.*, 2013b](#_ENREF_10); [Gill *et al.*, 2016](#_ENREF_11)). For example, *P. aeruginosa* (PAO1 strain) bacterial counts were higher in lung homogenates from db/db and ob/ob diabetic mice, streptozotocin-treated mice and alloxan-treated diabetic rats than in non-diabetic controls 6 hours after respiratory inoculation ([Gill *et al.*, 2016](#_ENREF_11); [Oliveira *et al.*, 2016](#_ENREF_27); [Pezzulo *et al.*, 2011](#_ENREF_32)). In humans, diabetes is associated with increased isolation of gram negative organisms in sputum from COPD patients and increased risk of lung colonisation with *P. aeruginosa* in patients with CF ([Leclercq *et al.*, 2014](#_ENREF_20); [Loukides *et al.*, 1996](#_ENREF_22)).

Airway glucose homeostasis therefore represents a new treatment target in the prevention and treatment of respiratory infection that has potential to reduce the use, or augment the effect, of antimicrobials. ASL glucose concentrations could be reduced by lowering blood glucose, reducing airway epithelial permeability to glucose or increasing glucose uptake by airway epithelial cells ([Garnett *et al.*, 2012](#_ENREF_7)). Acute (48 hours) metformin treatment reduced epithelial permeability to glucose by increasing expression of tight junction proteins ([Patkee *et al.*, 2016](#_ENREF_31)) and decreased *P. aeruginosa* and *S. aureus* growth in the lungs of diabetic mice, despite being of insufficient duration to lower blood glucose ([Garnett *et al.*, 2013a](#_ENREF_8); [Gill *et al.*, 2016](#_ENREF_11)). Sodium-glucose co-transporter isoform 2 (SGLT2) inhibitors are a relatively new class of anti-diabetic drug that lower blood glucose by increasing renal excretion of glucose and, unlike metformin, do not appear to have off-target effects in the lung ([Madaan *et al.*, 2016](#_ENREF_24)). The primary aim of our study was to determine whether reduction of blood glucose by treatment with the SGLT2 inhibitor dapagliflozin could reduce ASL glucose and *P. aeruginosa* infection in the lungs of diabetic mice. Secondary aims were to determine the effects of dapagliflozin on inflammation, in the mouse lung, glucose transport and fluid absorption in the rat lung, to assess the pulmonary effects of this drug.

**Materials and methods**

**Animals**14-15 weeks old male db/db mice (BKS.Cg-m+/+Leprdb/J  (db/db) C57BL/6J) (Charles River, Italy) average weight 49.7±0.5g and wild type C57BL/6J (24.0±3.0g) mice were used in the study. Wild type and db/db mice were were allocated upon arrival into groups using restricted randomization so that average body weights were similar between the groups. Based on power calculations using data from similar studies 7-10 animals were used per group to detect meaningful differences. Treatment groups were blinded during result assessment and in some but not all data analyses. Results from studies repeated using the same procedures were pooled where possible. There was no significant loss of animals with any treatment. However, there were occasional unexplained losses of animals during the study which contributed to the difference in numbers (n) given per group. Male Wistar rats (Charles River Laboratories, Kent, UK), average weight 375.9±19.4g were randomly allocated to treatment groups of 4 animals based on previous data. Animals were housed in pathogen free facilities in cages with wooden chips, shredded paper, gnaw sticks and plastic houses which were maintained at 21±2°C with 55±15% relative humidity and 12h light/dark cycle. Water and food (RM3 pellet from Lantmännen, Sweden or RM1 expanded pellets from SDS, UK) were available *ad libitum.* Body weights in fed state were recorded during the course of the study to follow the wellbeing of the animals. Experiments were terminated if body weight decreased by 15% and/or if animals showed signs of distress, such as decreased movement, abnormal posture, dull eyes or piloerection.

**LPS challenge model**

Lipopolysaccharide (LPS) challenge of 48 hours versus no challenge (indicated as time 0) was carried out in C57BL/6J and db/db mice, with or without dapagliflozin treatment (see below). LPS from *P.* *aeruginosa* (Sigma-Aldrich, UK) was diluted in aqueous solution to give 0.0875μg/g mouse in 50μl (based on the average weight of the group) and given by intranasal dosing at time 0. Animals were anaesthetised with isoflurane 4-5% (O2 1.2 L/min) prior to administration of the LPS solution to one nostril, which was subsequently inhaled naturally. Mice were then returned to their cages when retaining consciousness.

**Infection model**

Db/db and WT C57BL/6J mice were anaesthetised with isoflurane 4-5% (O2 1.2 L/min) prior to intranasal infection with vehicle or 105 CFU of log phase *P. aeruginosa* (PAO1) in 100μl. Mice were then returned to their cages when retaining consciousness. Bronchoalveolar lavage fluid (BALF) was obtained from inoculated lungs 24 hours later (see below). Lungs were then removed and homogenized by passage through 100μm cell strainers. Bacterial colony forming units (CFU) were determined in untreated BALF and lung homogenate by serial dilution on Luria broth agar (Sigma-Aldrich, UK).

**Blood and BAL fluid (BALF) collections**

Blood was collected from the vena saphena of conscious mice for glucose evaluation after 4 hours of fasting. Animals were euthanized by an i.p. overdose of 0.2ml pentobarbital (100mg/ml). The lungs of each animal were subjected to bronchoalveolar lavage. In brief, the trachea was exposed and a catheter was inserted and secured with a silk suture. Three volumes of 0.3ml saline were instilled, gently aspirated, pooled and weighed. There were occasions where BALF collection was impaired and sufficient samples volumes could not be obtained for analysis.

**BALF glucose, lactate and cell analysis**

The BALF was centrifuged at 1200rpm (314g), 10min, 4°C. The supernatant was used to measure glucose and lactate concentration on the ABX Pentra 400 (Horiba ABX Medical, Kyoto, Japan) according to the manufacturer’s protocol. The pellet was re-suspended in 0.25ml of PBS and the total and differential cell count was performed using SYSMEX XT-1800i Vet which uses fluorescent flow cytometry technology to differentiate between cell types (SYSMEX, Kobe Japan). For the infection studies, BALF was treated with red blood cell lysis buffer before centrifugation at 200x*g* for 5 minutes. Cells were resuspended in RPMI medium with 10% fetal calf serum and viable cell numbers determined by trypan blue exclusion. For differential cell counts, 100μl of cells from BALF and the lung homogenate were centrifuged onto glass slides, air dried and fixed in methanol before staining of with haematoxylin and eosin**.** Cell count is expressed as the amount of cells per ml of recovered BALF. At termination, blood from behind the eye was collected in EDTA tubes and blood glucose was measured directly using Accu-check (Roche, Bromma, Sweden). Plasma lactate was assayed using the ABX Pentra 400.

**Treatment with dapagliflozin**

Treatment groups were given a daily oral dose of either vehicle (sterile water) or dapagliflozin (1mg/kg) for 4 (LPS study) or 7 days (infection study) at a volume of 0.2mL/mouse. Dapagliflozin/vehicle was administered just prior to the LPS challenge and 4 hours before the *P. aeruginosa* infection.

Dapagliflozin concentrations in acetonitrile precipitated plasma samples were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). A gradient elution on a C18 column was used with acetonitrile/formic acid as the mobile phase system. The mass spectrometer operated in a positive/negative switching mode. Dapagliflozin plasma concentrations were 542±83nM, n=10 which is comparable to maximum plasma concentrations recorded in people (100-150ng/ml) ([Tirucherai *et al.*, 2016](#_ENREF_36); [Yang *et al.*, 2013](#_ENREF_39)).

**Perfused fluid filled rat lung**

Rats were terminally anesthetised with intra-peritoneal injections of 75mg/kg ketamine (100mg/ml)/1mg/kg medetomidine (1mg/ml). Tracheotomy was performed, the rats ventilated with air (Harvard Rodent ventilator) and the chest opened in the midline. The animal was then heparinized (0.1ml, 10,000 units/ml), cannulated via the pulmonary artery and left ventricle, and the lungs perfused with a solution containing 3% bovine serum albumin, 117mM NaCl, 2.68mM KCl, 1.25mM MgSO4, 1.82mM CaCl2, 20mM NaHCO3, 5.55mM glucose and 12mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). The time of loss of circulation to the lung was ~ 10-20 seconds. The perfusate (100ml) was maintained at 38oC, 95% O2 / 5% CO2 andcirculated with a perfusion pressure of 7-8mmHg and venous negative return pressure. Once perfusion was established, ventilation was stopped and the lung lumen filled with perfusate solution (15ml/kg body weight) with the exclusion of glucose. After a 40 minute mixing period to degas the lung, the BALF was sampled (150l) every 10 minutes and the concentration of glucose measured using an Analox GM9D glucose analyser (Analox Instruments Ltd). At 80 minutes, dapagliflozin (100nM) or the sodium glucose co-transporter isoform 1 and 2 (SGLT1/2) inhibitor phlorizin (100µM) was added to the BALF and further samples were taken at 10 minute intervals up to 150 minutes to determine the specificity of dapagliflozin and/or any detrimental off-target effects. Perfusion and venous pressures and perfusate flow rates as well as osmolality of the perfusate were monitored during the course of the experiment.

All experiments were performed under licence from the United Kingdom Home Office in accordance with the Animals (Scientific Procedures) Act 1986, amended 2012 or were approved by the local Ethical committee in Gothenburg (184-2012).

**Statistical analysis**

Values are reported as the mean±SEM. Statistical analysis was performed using analysis of variance (ANOVA) tests followed by Bonferroni’s multiple comparison post hoc tests (GraphPad Prism) or Student’s *t* test (only if F achieved P<0.05 and there was no significant variance in homogeneity). *P* values of <0.05 were considered statistically significant. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology ([Curtis *et al.*, 2015](#_ENREF_5)).

**Results**

**Diabetic db/db mice display elevated BALF glucose and lactate concentrations**

Fasting blood glucose concentrations were higher in db/db than C57BL/6J wild type mice (20.36±2.6, n=10compared to 7.20±0.0.18mM, p<0.05, n=10, Figure 1a) as were BALF glucose concentrations (0.45±0.08 compared to 0.05±0.01mM, p<0.05, n=10 and n=10 respectively, Figure 1b). Fasting lactate concentration was significantly higher in the BALF from db/db mice than from wild type (0.18±0.02 compared to 0.05±0.01mM, p<0.05, n=10 respectively, Figure 1c).

**Dapagliflozin reduces both fasting blood glucose and BALF glucose concentrations in db/db mice**

Treatment of db/db mice with dapagliflozin for 4 days had no significant effect on body weight (n=10, Figure 2a). Dapagliflozin significantly reduced fasting blood glucose concentration in db/db mice (from 21.61±1.86 to 11.40±0.69mM, p<0.05, n=18 and n=20 respectively, Figure 2b). Dapagliflozin reduced the BALF glucose concentration of db/db mice (from 0.28±0.04 to 0.15±0.01mM, p<0.05, n=20 respectively, Figure 2c). Dapagliflozin had no effect on the lactate concentration in the BALF of db/db mice (n=10 respectively). The positive relationship between blood glucose and BALF glucose in db/db mice was not altered by dapagliflozin. Lines of linear regression were significantly different from 0 (r2=0.3, p<0.05and r2=0.5, p<0.05) respectively, but not different from each other (Figure 3). It was noted however, that data from one individual with a blood glucose of 19.90 mM and BALF glucose of 0.22mM may have skewed the data. If this point is removed then the data analysis indicates that dapagliflozin promotes a lower BALF glucose concentration for any corresponding blood glucose than in untreated db/db mice with the slope of the line and x intercept closer to that of untreated wild type mice (data not shown). This would infer that dapagliflozin had a beneficial effect on ASL glucose homeostasis additional to its action on blood glucose concentration. However, we could not find any experimental justification to remove this point. Dapagliflozin had no effect on body weight, blood glucose or BALF glucose concentration in wild type mice (n=10, data not shown).

**Lowering blood glucose with dapagliflozin reduces *P. aeruginosa* infection in db/db mouse lung**

There was a significant increase in *P. aeruginosa* CFU recovered from the BALF of db/db mice compared to wild type (1504±172 and 736±96 CFU/ml, p<0.05, n=10 respectively, Figure 4a). Pre-treatment with dapagliflozin reduced bacteria in BALF of db/db mice to that seen in wild type (856±92CFU/ml, p<0.05, n=10, Figure 4a). Dapagliflozin had no effect on CFU in wild type (n=10, data not shown) or survival in any group (n=10, data not shown). Dapagliflozin did not alter the inflammatory response to *P. aeruginosa* infection. White blood cells (WBC) were significantly increased in db/db and dapagliflozin-treated db/db mice (p<0.05, n=10 respectively) compared to wild type and the elevation was predominantly due to an increase in neutrophils (Figure 4b&c). Based on these observations, we suggest that dapagliflozin reduced bacterial load through its action on blood and airway glucose.

**Diabetic db/db mice exhibit more airway inflammation which is not modified by dapagliflozin**

Reduction of inflammation is a treatment target in diabetes. We therefore explored whether dapagliflozin treatment could modify underlying inflammation in db/db mice and/or the acute response to an inflammatory stimulus (identified by increased inflammatory cells and lactate concentration in BALF) to ensure that it did not promote inflammation and to see if it could reduce inflammation. To do this we used LPS from *P. aeruginosa* to mimic the bacterial insult. Without LPS treatment, db/db mice had higher numbers of WBC in the BALF than wild type mice (0.17±0.01 compared to 0.11±0.01x106 cells/ml weight, p<0.05, n=32 and 24 respectively, Figure 5a). This was predominantly due to increased macrophages (Figure 5b, n=32).

Treatment of WT and db/db with intranasal LPS elicited an increase in inflammatory cells in BALF (all n=6, Figure 5). The response to LPS in db/db mice was more robust than that of WT mice and was characterised by increased numbers of neutrophils, macrophages and eosinophils (Figure 5c&d). These data indicate that db/db mice had more baseline inflammatory cells in the lungs than WT mice and elicited a more robust neutrophil inflammatory response to LPS stimulation.

Pre-treatment with dapagliflozin had no effect on inflammatory cells in the BALF of db/db (n=10, Figure 6a-d). Dapagliflozin also had no effect on the LPS-induced increase in total WBC, neutrophils, macrophages or eosinophils numbers in the BALFs of db/db mice, n=10 respectively (Figure 6a-d) .

BALF lactate concentration was increased in LPS-treated db/db mice (0.12±0.01, n=16 to 0.28±0.02 mM, p<0.05, n=17, Figure 7a). As expected, the number of WBC positively correlated with lactate concentration in the BALF of db/db mice (r2=0.3, p<0.05, (Figure 7b). Dapagliflozin had no effect on the LPS-induced rise in lactate concentration in the BALF and concentrations remained elevated at 0.24±0.02 mM, n=10 (Figure 7c). Therefore, whilst dapagliflozin pre-treatment lowered blood and airway glucose, it had no effect on the elevated inflammation seen in db/db animals. Treatment of db/db mice with LPS had no effect on blood (n=14) or BALF glucose concentration (n=12, Figure 7a & b).

**SGLT2 inhibitor dapagliflozin has no detrimental effect on lung glucose and fluid absorption**

To confirm the specificity of dapagliflozin as an inhibitor of SGLT2, without effect on the function of SGLT1, we measured BALF glucose in perfused, fluid-filled rat lungs, with and without addition of dapagliflozin (SGLT2-specific inhibitor) or phlorizin (SGLT1/2 inhibitor) to the lung instillate. There was no significant change in lung liquid glucose concentration in the presence of dapagliflozin (0.11±0.02mM at the end of control sampling to 0.15±0.07nM at the end of treatment sampling, n=4) or lung liquid absorption rate (control rate: -0.02±0.00ml/min/g dry lung weight to treatment rate: -0.02±0.00ml/min/g dry lung weight, n=4). Phlorizin significantly increased lung liquid glucose (0.05±0.01mM at the end of control sampling to 0.36±0.05 mM at the end of treatment sampling; p <0.05, n=6, Figure 8a) and significantly decreased lung liquid absorption rate (control rate: -0.02±0.00 ml/min/g dry lung weight to treatment rate: -0.01±0.00 ml/min/g dry lung weight; p<0.05, n=6, Figure 8b). These data demonstrate that SGLT1, but not SGLT2, mediates Na+/glucose transport in the rat lung and that dapagliflozin has no effect on this process.

**Discussion**

We found that reduction of blood glucose by treatment with the SGLT2 inhibitor dapagliflozin reduced both BALF glucose concentrations and *P. aeruginosa* load in the lungs of leptin receptor-deficient db/db diabetic mice. To our knowledge this is the first study to demonstrate that control of blood glucose using an oral hypoglycaemic agent can prevent pulmonary infection, potentially by limiting movement of glucose into airway secretions.

We propose that dapagliflozin exerts its anti-infective effect by restricting glucose availability for *P. aeruginosa* growth/survival in the lung through a reduction in blood and ASL glucose concentrations. In support of this, genetic impairment of sugar transport pathways in *P. aeruginosa* and *S. aureus* that limited sugar uptake, had a similar effect on bacterial growth/survival in the lung to that of dapagliflozin ([Garnett *et al.*, 2014](#_ENREF_9); [Gill *et al.*, 2016](#_ENREF_11); [Pezzulo *et al.*, 2011](#_ENREF_32)) . Reduction of airway glucose in the distal mouse lung by manipulation of glucose transport pathways also reduced bacterial load ([Oliveira *et al.*, 2016](#_ENREF_27)). Furthermore, we previously showed that treatment with the biguanide metformin reduced lung epithelial permeability and glucose flux into the lung lumen without affecting blood glucose concentration and inhibited the growth/survival of *S. aureus* and *P. aeruginosa* in diabetic mice ([Garnett *et al.*, 2013a](#_ENREF_8); [Patkee *et al.*, 2016](#_ENREF_31)). Our new data indicate that lowering blood glucose concentration and consequently the gradient for glucose diffusion into the lung lumen, has a similar effect to reducing epithelial permeability and glucose flux, resulting in restriction of bacterial growth/survival in the lungs. As dapagliflozin and metformin have different modes of action, it could be speculated that combined therapy would further reduce ASL glucose and infection. We have no evidence that insulin or insulin-sensitising effects of metformin and other type II diabetic drugs would further modify ASL glucose, although other beneficial effects cannot be ruled out.

These findings have potentially important clinical relevance and implications for human health. Diabetes mellitus affects ~25% people with COPD ([Wells *et al.*, 2013](#_ENREF_38)) and ~50% adults with CF ([Li *et al.*, 2016](#_ENREF_21)), in whom it is associated with increased exacerbation rate ([Kinney *et al.*, 2014](#_ENREF_17)) and increased sputum colonisation with gram negatives*/P. aeruginosa* ([Leclercq *et al.*, 2014](#_ENREF_20); [Loukides *et al.*, 1996](#_ENREF_22)). Several very small studies in patients with chronic lung disease indicate that treatment with oral hypoglycaemics and/or insulin can reduce exacerbation rate and alter sputum microbiology ([Lanng *et al.*, 1994](#_ENREF_19); [Rinne *et al.*, 2015](#_ENREF_33)). SGLT2 inhibitors have established application in the treatment of type 2 diabetes in COPD ([NICE, 2013](#_ENREF_26)) and potential application as an insulin adjunct in the treatment of the insulin-deficient diabetes seen in CF ([Argento *et al.*, 2016](#_ENREF_1)). Further investigation of the effect of dapagliflozin on chronic *P. aeruginosa* infection and the safety and efficacy of treatment with this drug in co-morbid diabetes and respiratory disease are now required. This together with progress to a clinical investigation will determine whether blood glucose control with dapagliflozin can reduce *P. aeruginosa* load/colonisation and/or exacerbation rate in patients with chronic lung disease.

This study has also generated important lung safety data. Dapagliflozin had no effect on inflammatory cell numbers and associated lactate concentration in the airways of mice prior to, or after, an acute pro-inflammatory challenge. This indicates that dapagliflozin did not impair the inflammatory response required to clear infection. Inflammatory cells and lactate were increased in the lungs of untreated db/db mice and exposure to pro-inflammatory stimuli promoted a characteristically neutrophilic response that was more robust compared to wild type animals ([Lu *et al.*, 2006](#_ENREF_23); [Vernooy *et al.*, 2010](#_ENREF_37); [Yano *et al.*, 2012](#_ENREF_40)). This difference in inflammatory response was not reported for hyperglycaemic GK+/- or streptozotocin-treated mice ([Gill *et al.*, 2016](#_ENREF_11); [Hunt *et al.*, 2014](#_ENREF_14)) and indicates that lack of leptin receptor signalling and/or insulin-resistance are more likely than glucose to mediate this effect in db/db mice ([Lu *et al.*, 2006](#_ENREF_23); [Park *et al.*, 2009](#_ENREF_29); [Vernooy *et al.*, 2010](#_ENREF_37); [Yano *et al.*, 2012](#_ENREF_40)). Increased inflammatory status is a hallmark of diabetic patients and reduction of systemic inflammation has been proposed as a treatment target ([Maiorino *et al.*, 2016](#_ENREF_25)). Although, there is no data from human studies yet ([Scheen *et al.*, 2015](#_ENREF_35)), inhibition of SGLT1/2 was reported to improve systemic neutrophil phagocytosis in db/db mice ([Yano *et al.*, 2012](#_ENREF_40)) and treatment with the SGLT2 inhibitor empagliflozin for 8 weeks (compared to 4 days used in this study), improved insulin sensitivity ([Kern *et al.*, 2016](#_ENREF_16)). Thus, whether a more prolonged treatment with dapagliflozin would aid resolution of inflammation or improve inflammatory cell function requires further study.

In the well-characterised perfused, fluid-filled rat lung model, we found that dapagliflozin had no adverse effects on fluid absorption or lung glucose concentrations. The SGLT1 isoform is expressed in alveolar epithelium, where it contributes to sodium, glucose and fluid absorption ([Bodega *et al.*, 2010](#_ENREF_3)). Phlorizin, an inhibitor of SGLT1/2, reduced lung liquid and glucose absorption, increasing luminal glucose concentrations with potential adverse effects of pulmonary oedema and increased bacterial proliferation ([Oliveira *et al.*, 2016](#_ENREF_27)). Dapagliflozin, which has ~200-fold selectivity for SGLT2 over SGLT1 ([Han *et al.*, 2008](#_ENREF_13)) had no effect on lung fluid or glucose absorption, providing further evidence for pulmonary safety of this drug and no function of SGLT2 in the lung.

We conclude that dapagliflozin reduces bacterial growth/survival in the lung by reducing glucose availability in the ASL. Dapagliflozin reduced blood and BALF glucose without negatively impacting lung glucose transport, fluid absorption or inflammatory responses in the lung. This is the first study to show that reduction of blood glucose in hyperglycaemia has a direct beneficial effect on respiratory infection *in vivo.* These findings are relevant to the management and treatment diabetic exacerbation of respiratory disease particularly in the light of increasing bacterial resistance to antibiotic therapy.

**AUTHOR CONTRIBUTIONS**

DB, EB, JT, JG & AA were responsible for study concept. AA, CW, AB, JT, HG, SG, MOW, DW, AL, DS carried out studies and analysed data. DB collated data and prepared manuscript with input from AA, EB, JT and JG.

**Acknowledgements**

Funded by a Medical Research Council Industrial Collaboration Award with AstraZeneca Gothenburg, Sweden (MR/K012770/1). SG is supported by an Imperial College Anti-microbial resistance consortium (ARC) fellowship, HG is supported by an MRC DTP award to Imperial College.

**CONFLICTS OF INTEREST STATEMENT**

None

**REFERENCES**

Argento NB, Nakamura K (2016). Glycemic Effects of Sglt-2 Inhibitor Canagliflozin in Type 1 Diabetes Patients Using the Dexcom G4 Platinum Cgm. *Endocr Pract* **22**(3)**:** 315-322.

Baker EH, Clark N, Brennan AL, Fisher DA, Gyi KM, Hodson ME*, et al.* (2007). Hyperglycemia and cystic fibrosis alter respiratory fluid glucose concentrations estimated by breath condensate analysis. *J Appl Physiol* **102**(5)**:** 1969-1975.

Bodega F, Sironi C, Armilli M, Porta C, Agostoni E (2010). Evidence for Na+-glucose cotransporter in type I alveolar epithelium. *Histochem Cell Biol* **134**(2)**:** 129-136.

Briggs EC, Nguyen T, Wall MA, MacDonald KD (2012). Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience. *Clin Respir J* **6**(1)**:** 56-64.

Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA*, et al.* (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. *Br J Pharmacol* **172**(14)**:** 3461-3471.

Franzese A, Valerio G, Buono P, Spagnuolo MI, Sepe A, Mozzillo E*, et al.* (2008). Continuous glucose monitoring system in the screening of early glucose derangements in children and adolescents with cystic fibrosis. *J Pediatr Endocrinol Metab* **21**(2)**:** 109-116.

Garnett JP, Baker EH, Baines DL (2012). Sweet talk - insights into the nature & importance of glucose transport in lung epithelium. *Eur Respir J* **40**(5)**:** 1269-1276.

Garnett JP, Baker EH, Naik S, Lindsay JA, Knight GM, Gill S*, et al.* (2013a). Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose. *Thorax* **68**(9)**:** 835-845.

Garnett JP, Braun D, McCarthy AJ, Farrant MR, Baker EH, Lindsay JA*, et al.* (2014). Fructose transport-deficient Staphylococcus aureus reveals important role of epithelial glucose transporters in limiting sugar-driven bacterial growth in airway surface liquid. *Cell Mol Life Sci* **71**((23))**:** 4665-4673.

Garnett JP, Gray MA, Tarran R, Brodlie M, Ward C, Baker EH*, et al.* (2013b). Elevated paracellular glucose flux across cystic fibrosis airway epithelial monolayers is an important factor for Pseudomonas aeruginosa growth. *PLoS One* **8**(10)**:** e76283.

Gill SK, Hui K, Farne H, Garnett JP, Baines DL, Moore LS*, et al.* (2016). Increased airway glucose increases airway bacterial load in hyperglycaemia. *Sci Rep* **6:** 27636.

Gudmundsson G, Gislason T, Lindberg E, Hallin R, Ulrik CS, Brondum E*, et al.* (2006). Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. *Respir Res* **7:** 109.

Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA*, et al.* (2008). Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. *Diabetes* **57**(6)**:** 1723-1729.

Hunt WR, Zughaier SM, Guentert DE, Shenep MA, Koval M, McCarty NA*, et al.* (2014). Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. *Am J Physiol Lung Cell Mol Physiol* **306**(1)**:** L43-49.

Jarad NA, Giles K (2008). Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis. *Chron Respir Dis* **5**(1)**:** 29-33.

Kern M, Kloting N, Mark M, Mayoux E, Klein T, Bluher M (2016). The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. *Metabolism* **65**(2)**:** 114-123.

Kinney GL, Black-Shinn JL, Wan ES, Make B, Regan E, Lutz S*, et al.* (2014). Pulmonary function reduction in diabetes with and without chronic obstructive pulmonary disease. *Diabetes Care* **37**(2)**:** 389-395.

Kupeli E, Ulubay G, Ulasli SS, Sahin T, Erayman Z, Gursoy A (2010). Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. *Endocrine* **38**(1)**:** 76-82.

Lanng S, Thorsteinsson B, Nerup J, Koch C (1994). Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. *Acta Paediatr* **83**(8)**:** 849-853.

Leclercq A, Gauthier B, Rosner V, Weiss L, Moreau F, Constantinescu AA*, et al.* (2014). Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients. *J Cyst Fibros* **13**(4)**:** 478-484.

Li CY, Erickson SR, Wu CH (2016). Metformin use and asthma outcomes among patients with concurrent asthma and diabetes. *Respirology*. Epub ahead of print

Loukides S, Polyzogopoulos D (1996). The effect of diabetes mellitus on the outcome of patients with chronic obstructive pulmonary disease exacerbated due to respiratory infections. *Respiration* **63**(3)**:** 170-173.

Lu FL, Johnston RA, Flynt L, Theman TA, Terry RD, Schwartzman IN*, et al.* (2006). Increased pulmonary responses to acute ozone exposure in obese db/db mice. *Am J Physiol Lung Cell Mol Physiol* **290**(5)**:** L856-865.

Madaan T, Akhtar M, Najmi AK (2016). Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. *Eur J Pharm Sci* **93:** 244-252.

Maiorino MI, Bellastella G, Giugliano D, Esposito K (2016). Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit? *Endocrine*. Epub ahead of print

NICE (2013). Dapagliflozin in combination therapy for treating type 2 diabetes.

Oliveira TL, Candeia-Medeiros N, Cavalcante-Araujo PM, Melo IS, Favaro-Pipi E, Fatima LA*, et al.* (2016). SGLT1 activity in lung alveolar cells of diabetic rats modulates airway surface liquid glucose concentration and bacterial proliferation. *Sci Rep* **6:** 21752.

Parappil A, Depczynski B, Collett P, Marks GB (2010). Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. *Respirology* **15**(6)**:** 918-922.

Park S, Rich J, Hanses F, Lee JC (2009). Defects in innate immunity predispose C57BL/6J-Leprdb/Leprdb mice to infection by Staphylococcus aureus. *Infect Immun* **77**(3)**:** 1008-1014.

Parkins MD, Rendall JC, Elborn JS (2012). Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. *Chest* **141**(2)**:** 485-493.

Patkee WR, Carr G, Baker EH, Baines DL, Garnett JP (2016). Metformin prevents the effects of Pseudomonas aeruginosa on airway epithelial tight junctions and restricts hyperglycaemia-induced bacterial growth. *J Cell Mol Med* **20**(4)**:** 758-764.

Pezzulo AA, Gutierrez J, Duschner KS, McConnell KS, Taft PJ, Ernst SE*, et al.* (2011). Glucose depletion in the airway surface liquid is essential for sterility of the airways. *PLoS One* **6**(1)**:** e16166.

Rinne ST, Liu CF, Feemster LC, Collins BF, Bryson CL, O'Riordan TG*, et al.* (2015). Thiazolidinediones are associated with a reduced risk of COPD exacerbations. *Int J Chron Obstruct Pulmon Dis* **10:** 1591-1597.

Sawicki GS, Ayyagari R, Zhang J, Signorovitch JE, Fan L, Swallow E*, et al.* (2013). A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care. *Pediatr Pulmonol* **48**(10)**:** 954-961.

Scheen AJ, Esser N, Paquot N (2015). Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. *Diabetes Metab* **41**(3)**:** 183-194.

Tirucherai GS, LaCreta F, Ismat FA, Tang W, Boulton DW (2016). Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus. *Diabetes Obes Metab* **18**(7)**:** 678-684.

Vernooy JH, Bracke KR, Drummen NE, Pauwels NS, Zabeau L, van Suylen RJ*, et al.* (2010). Leptin modulates innate and adaptive immune cell recruitment after cigarette smoke exposure in mice. *J Immunol* **184**(12)**:** 7169-7177.

Wells C, Baker E (2013). Metabolic syndrome and diabetes mellitus in COPD. *European Respiratory Monographs* **59:** 117-134.

Yang L, Li H, Bui A, Chang M, Liu X, Kasichayanula S*, et al.* (2013). Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. *Clin Ther* **35**(8)**:** 1211-1222 e1212.

Yano H, Kinoshita M, Fujino K, Nakashima M, Yamamoto Y, Miyazaki H*, et al.* (2012). Insulin treatment directly restores neutrophil phagocytosis and bactericidal activity in diabetic mice and thereby improves surgical site Staphylococcus aureus infection. *Infect Immun* **80**(12)**:** 4409-4416.

**Figure legends**

**Figure 1. Airway glucose and lactate concentrations are elevated in hyperglycaemic mice.** a) Blood glucose, b) BALF glucose and c) BALF lactate all shown as mM and plotted for individual C57BL/6J wild type (black circles) or db/db mice (open squares) (all n=10). The horizontal lines indicate mean values±SEM. Statistically different from wild type or db/db treated with saline, \* p<0.05.

**Figure 2**. **Treatment with dapagliflozin reduces both blood and airway glucose**. a) Body weight (n=10), b) fasting blood glucose (n=18 and n=20), c) BALF glucose (both n=20) and d) BALF lactate (n=10). Body weight is shown as mean±SEM at the start and end of the dapagliflozin treatment protocolAll others are plotted as individual db/db mice treated with vehicle (squares) or dapagliflozin (dapa: triangles). The horizontal lines indicate mean values±SEM. Statistical difference between groups is indicated \* p<0.05.

**Figure 3.** **Dapagliflozin does not adversely affect the relationship between blood glucose and BALF glucose concentration**. Values for blood glucose and BALF glucose concentration plotted for individual untreated (open squares) (n=20) or dapagliflozin pre-treated db/db mice (open triangles)(n=21). Lines of linear regression were significantly different from 0 (r2=0.3, p<0.05. and r2=0.5, p<0.01) respectively (solid lines), but not different from each other and a single line of regression (broken line) could be plotted for all data (r2=0.5, p<0.0001).

**Figure 4**. **Dapagliflozin treatment reduces airway bacterial load.** C57BL/6J wild type (black circles) or db/db mice pre-treated for 7 days with vehicle (open symbols) or dapagliflozin (open triangles) were infected intranasally with *P. aeruginosa*. a) *P. aeruginosa* CFU, b) Total white blood cells (WBC), c) Neutrophils in BALF. Data are plotted for individual animals 24 hours after infection (all n=10). The horizontal lines indicate mean values±SEM. Statistical difference between groups is indicated \*p<0.05.

**Figure 5. Hyperglycaemic animals have greater neutrophil response to LPS.**  a) Total white blood cells (WBC), b) Macrophages c) Neutrophils, d) Eosinophils, all shown as x 106/ml and plotted for individual C57BL/6J wild type (black circles) or db/db mice (open squares) treated (n=24 and n=32 respectively) with saline or LPS (both n=6). The horizontal lines indicate mean values±SEM. Statistical differences between groups are indicated \* p<0.05.

**Figure 6.** **Dapagliflozin treatment does not reduce airway inflammatory cells.** a) Total white blood cells (WBC), b) Macrophages, c) Neutrophils, d) Eosinophils all shown as x106/ml and plotted for individual vehicle-treated db/db mice (open squares) or db/db mice pre-treated with dapagliflozin (dapa; open triangles) or LPS (black squares) or dapa + LPS (black triangles)(all n=10). The horizontal lines indicate mean values±SEM. Statistical differences between groups are indicated \* p< 0.05

**Figure 7. Dapagliflozin treatment does not change BALF lactate concentration.** a)Vehicle-treated db/db mice (n=16), or db/db mice pre-treated with dapagliflozin (dapa; open triangles)(n=17) or LPS (black squares)(n=10) or dapa + LPS (black triangles)(n=10) b)Lactate concentration (mM) vs white blood cells (WBC) plotted for individual vehicle-treated (open squares)(n=10) or LPS-treated (black squares)(n=40) db/db mice. The horizontal lines indicate mean values±SEM. Statistical differences between groups are indicated \* p< 0.05.

**Figure 8. Dapagliflozin does not directly modify glucose transport or fluid homeostasis in the lung.** a) Upper axes, perfusate glucose concentration, Lower axes, BALF glucose concentration in the lungs of rats treated with vehicle (control), or phlorizin (PZ) or dapagliflozin (DAPA) over an experimental time course of 150 minutes. A baseline was established over the first 40 minutes and vehicle or drugs were added as shown by the vertical dotted line. b) Normalised Jv for vehicle (control) or phlorizin (PZ) or dapagliflozin (DAPA) in the same experiment as described above. Data are shown as mean±SEM. Significantly different from corresponding control samples, \* p<0.05.

Figure 1



Figure 2

Figure 3



Figure 4



Figure 5



Figure 6



Figure 7.







Figure 8

